These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3806788)

  • 1. Detection of asymptomatic herpes simplex virus infections after vaccination.
    Ashley R; Mertz GJ; Corey L
    J Virol; 1987 Feb; 61(2):264-8. PubMed ID: 3806788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral immune response to herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine.
    Ashley R; Mertz G; Clark H; Schick M; Salter D; Corey L
    J Virol; 1985 Nov; 56(2):475-81. PubMed ID: 2997470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of Herpes Simplex Virus Glycoprotein D Antibodies to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines.
    Mahant AM; Guerguis S; Blevins TP; Cheshenko N; Gao W; Anastos K; Belshe RB; Herold BC
    J Infect Dis; 2022 Nov; 226(9):1489-1498. PubMed ID: 35834278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes simplex virus type-2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans.
    Mertz GJ; Peterman G; Ashley R; Jourden JL; Salter D; Morrison L; McLean A; Corey L
    J Infect Dis; 1984 Aug; 150(2):242-9. PubMed ID: 6088648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of asymptomatic initial herpes simplex virus (HSV) infections in animals immunized with subunit HSV glycoprotein vaccines.
    Bernstein DI; Ashley RL; Stanberry LR; Myers MG
    J Clin Microbiol; 1990 Jan; 28(1):11-5. PubMed ID: 2153698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans.
    Cairns TM; Huang ZY; Whitbeck JC; Ponce de Leon M; Lou H; Wald A; Krummenacher C; Eisenberg RJ; Cohen GH
    J Virol; 2014 Nov; 88(21):12612-22. PubMed ID: 25142599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral immune response to HSV-1 and HSV-2 viral proteins in patients with primary genital herpes.
    Ashley R; Benedetti J; Corey L
    J Med Virol; 1985 Oct; 17(2):153-66. PubMed ID: 2997384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HVEM signaling promotes protective antibody-dependent cellular cytotoxicity (ADCC) vaccine responses to herpes simplex viruses.
    Burn Aschner C; Loh LN; Galen B; Delwel I; Jangra RK; Garforth SJ; Chandran K; Almo S; Jacobs WR; Ware CF; Herold BC
    Sci Immunol; 2020 Aug; 5(50):. PubMed ID: 32817296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.
    Corey L; Langenberg AG; Ashley R; Sekulovich RE; Izu AE; Douglas JM; Handsfield HH; Warren T; Marr L; Tyring S; DiCarlo R; Adimora AA; Leone P; Dekker CL; Burke RL; Leong WP; Straus SE
    JAMA; 1999 Jul; 282(4):331-40. PubMed ID: 10432030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection.
    Mertz GJ; Ashley R; Burke RL; Benedetti J; Critchlow C; Jones CC; Corey L
    J Infect Dis; 1990 Apr; 161(4):653-60. PubMed ID: 2181031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of type-specific antibody to herpes simplex virus type 1 by radioimmunoassay with herpes simplex virus type 1 glycoprotein C purified with monoclonal antibody.
    Arvin AM; Koropchak CM; Yeager AS; Pereira L
    Infect Immun; 1983 Apr; 40(1):184-9. PubMed ID: 6832831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected].
    Langenberg AG; Burke RL; Adair SF; Sekulovich R; Tigges M; Dekker CL; Corey L
    Ann Intern Med; 1995 Jun; 122(12):889-98. PubMed ID: 7755223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice.
    Ghiasi H; Kaiwar R; Nesburn AB; Slanina S; Wechsler SL
    J Virol; 1994 Apr; 68(4):2118-26. PubMed ID: 8138996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immune response to herpes simplex virus: comparison of the specificity and relative titers of serum antibodies directed against viral polypeptides following primary herpes simplex virus type 1 infections.
    Eberle R; Mou SW; Zaia JA
    J Med Virol; 1985 Jun; 16(2):147-62. PubMed ID: 2409225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine.
    Ashley RL; Crisostomo FM; Doss M; Sekulovich RE; Burke RL; Shaughnessy M; Corey L; Polissar NL; Langenberg AG
    J Infect Dis; 1998 Jul; 178(1):1-7. PubMed ID: 9652416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response to a DNA free herpes simplex vaccine in man.
    Cappel R; Sprecher S; Rickaert F; de Cuyper F
    Arch Virol; 1982; 73(1):61-7. PubMed ID: 6289778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.
    Cairns TM; Huang ZY; Gallagher JR; Lin Y; Lou H; Whitbeck JC; Wald A; Cohen GH; Eisenberg RJ
    J Virol; 2015 Sep; 89(18):9213-31. PubMed ID: 26109729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine.
    Kohl S; Charlebois ED; Sigouroudinia M; Goldbeck C; Hartog K; Sekulovich RE; Langenberg AG; Burke RL
    J Infect Dis; 2000 Jan; 181(1):335-9. PubMed ID: 10608784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.